Shattuck Labs (STTK) Liabilities and Shareholders Equity (2019 - 2026)
Shattuck Labs' (STTK) quarterly Liabilities and Shareholders Equity came in at $102.1 million in Q1 2026, up 32.34% year-on-year from $77.2 million in Q1 2025, and up 12.19% on a QoQ basis from $91.0 million in Q4 2025.
Shattuck Labs (STTK) Liabilities and Shareholders Equity (2019 - 2026) Analysis & Trends
Shattuck Labs (STTK) has 8 years of Liabilities and Shareholders Equity data on file, last reported at $102.1 million in Q1 2026.
- On a quarterly basis, Liabilities and Shareholders Equity rose 32.34% year-over-year to $102.1 million in Q1 2026; TTM through Mar 2026 was $357.9 million, a 12.41% decrease from a year earlier, with the FY2025 full-year figure at $91.0 million, changed 0.03% from the prior year.
- Liabilities and Shareholders Equity for Q1 2026 stood at $102.1 million, up from $91.0 million in the prior quarter.
- Over the last five years, Liabilities and Shareholders Equity for STTK reached as high as $270.5 million in Q1 2022 and fell as low as $64.4 million in Q2 2025.
- Historically, Liabilities and Shareholders Equity has averaged $146.2 million across 5 years, with a median of $130.5 million in 2023.
- Across the five-year window, Liabilities and Shareholders Equity sank 49.95% in 2025 and soared 32.34% in 2026, its largest moves.
- Year by year, Liabilities and Shareholders Equity stood at $205.3 million in 2022, then slipped by 22.29% to $159.6 million in 2023, then sank by 42.94% to $91.0 million in 2024, then slipped by 0.03% to $91.0 million in 2025, then increased by 12.19% to $102.1 million in 2026.
- Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $102.1 million in Q1 2026, $91.0 million in Q4 2025, and $100.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 311.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 78.88 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 8.55 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 39.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 26.48 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 40.87 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 811.27 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 10.03 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.25 Bn |
| 10 | Shattuck Labs | 795.74 Mn | 795.74 Mn | - | 102.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 102.12 Mn |
| Dec 31, 2025 | 91.03 Mn |
| Sep 30, 2025 | 100.33 Mn |
| Jun 30, 2025 | 64.37 Mn |
| Mar 31, 2025 | 77.17 Mn |
| Dec 31, 2024 | 91.05 Mn |
| Sep 30, 2024 | 111.72 Mn |
| Jun 30, 2024 | 128.61 Mn |
| Mar 31, 2024 | 146.34 Mn |
| Dec 31, 2023 | 159.56 Mn |
| Sep 30, 2023 | 130.46 Mn |
| Jun 30, 2023 | 155.27 Mn |
| Mar 31, 2023 | 177.68 Mn |
| Dec 31, 2022 | 205.32 Mn |
| Sep 30, 2022 | 222.94 Mn |
| Jun 30, 2022 | 251.34 Mn |
| Mar 31, 2022 | 270.49 Mn |
| Dec 31, 2021 | 298.59 Mn |
| Sep 30, 2021 | 310.57 Mn |
| Jun 30, 2021 | 323.78 Mn |